EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long‐Term Survival and Prognostic Factors of Stereotactic Body Radiotherapy Following Transarterial Chemoembolization for Hepatocellular Carcinoma

Hoang Dong Duc iD, Mai Binh Thanh, Mai Bang Hong, Nguyen Thinh Tien, Nguyen Thai Van, Bui Bieu Quang, Nguyen Chau Dinh, Thai Ky Doan

Cancer Reports · 2025

DOI: 10.1002/cnr2.70212 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2025. Verfasst von Hoang Dong Duc und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Thai Nguyen University of Medicine and Pharmacy, Thai Nguyen, Vietnam. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Radiosurgery. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims This study presents a detailed analysis of long‐term survival and critical factors influencing the outcomes of hepatocellular carcinoma patients treated with stereotactic body radiotherapy (SBRT) and transarterial chemoembolization (TACE). Our findings provide reassurance about the potential of the combination of TACE and SBRT as an effective treatment strategy for patients with large liver tumors due to HCC.

Methods

A prospective study was conducted on 42 patients with intermediate‐stage hepatocellular carcinoma (HCC) at 108 Military Central Hospital between December 2018 and June 2024. Following a single session of TACE, each patient underwent SBRT 1 month later. The SBRT dose ranged from 27.5 to 48 Gy, delivered in 3–5 fractions. The patient survival analysis was conducted using the Kaplan–Meier method while examining prognostic factors influencing survival, which involved log‐rank tests and Cox proportional hazards regression analysis.

Results

Among the 42 patients (83.3% male), 34 patients (81.0%) had tumors measuring ≥ 5 cm. The median follow‐up period was 32.2 months (4.5–65.1 months). The median overall survival (OS) was 32.6 months, with the respective 1‐, 3‐, and 5‐year OS rates reported as 73.8%, 24.5%, and 19.6%. Furthermore, the median progression‐free survival (PFS) was 16.6 months, with corresponding 1‐ and 3‐year PFS rates of 71.4% and 19.0%. Factors linked to improved OS and PFS included AFP levels and treatment response based on Modified RECIST criteria. Additionally, multivariate analysis identified patient age, EQD2, and BED10 as significant predictors of better survival outcomes.

Conclusions

Our study provides evidence supporting the effectiveness and safety of combining TACE and SBRT as a treatment strategy for patients with large liver tumors due to HCC, instilling confidence in the future of HCC treatment. Positive prognostic factors included patient age, EQD 2 , and BED 10 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsChemoembolization, TherapeuticRadiosurgeryHumansMaleFemaleMiddle AgedPrognosisAgedProspective StudiesAdultCombined Modality TherapyFollow-Up StudiesSurvival RateTreatment OutcomeAged, 80 and over

Stichwörter der Autor:innen

hepatocellular carcinomastereotactic body radiotherapytransarterial chemoembolization

Autor:innen und Institutionen

  • Department of Internal Medicine, Thai Nguyen University of Medicine and Pharmacy, Thai Nguyen, Vietnam.
  • Department of Gastroenterology and Hepatology, 108 Military Central Hospital, Hanoi, Vietnam.
  • Department of Radiation Oncology and Radiosurgery, 108 Military Central Hospital, Hanoi, Vietnam.

ORCID-Profile: Hoang Dong Duc

Zitieren

APA

Duc, H. D., Thanh, M. B., Hong, M. B., Tien, N. T., Van, N. T., Quang, B. B., Dinh, N. C., & Doan, T. K. (2025). Long‐Term Survival and Prognostic Factors of Stereotactic Body Radiotherapy Following Transarterial Chemoembolization for Hepatocellular Carcinoma. Cancer Reports. https://doi.org/10.1002/cnr2.70212

Vancouver

Duc HD, Thanh MB, Hong MB, Tien NT, Van NT, Quang BB, et al. Long‐Term Survival and Prognostic Factors of Stereotactic Body Radiotherapy Following Transarterial Chemoembolization for Hepatocellular Carcinoma. Cancer Reports. 2025. doi:10.1002/cnr2.70212

BibTeX
@article{Duc2025,
  author = {Duc, Hoang Dong and Thanh, Mai Binh and Hong, Mai Bang and Tien, Nguyen Thinh and Van, Nguyen Thai and Quang, Bui Bieu and Dinh, Nguyen Chau and Doan, Thai Ky},
  title = {Long‐Term Survival and Prognostic Factors of Stereotactic Body Radiotherapy Following Transarterial Chemoembolization for Hepatocellular Carcinoma},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70212}
}
Kostenlos starten →